Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate, ciltacabtagene autoleucel, or cilta-cel, is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma (NHL), acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, and a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. The company was founded in 2014 and is headquartered in Somerset, New Jersey. Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation.

Legend Biotech Corporation

In a report released today, Yaron Werber from TD Cowen maintained a Hold rating on Legend Biotech, with a price target of $24.00. According to TipR...

TD Cowen Sticks to Its Hold Rating for Legend Biotech (LEGN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Immunic (IMUX), Legend Biotech (LEGN) and Sagimet Bi...

Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), Legend Biotech (LEGN) and Sagimet Biosciences, Inc. Class A (SGMT)

Legend Biotech ( ($LEGN) ) has shared an announcement. Legend Biotech disclosed that its board appointed Alan Bash as interim chief executive offic...

Legend Biotech Details Compensation Package for Interim CEO Alan Bash

Deutsche Bank analyst Thomas Rothausler maintained a Buy rating on LEG Immobilien today and set a price target of €67.00. According to TipRanks, Ro...

Deutsche Bank  Sticks to Its Buy Rating for LEG Immobilien (0QC9)

Berenberg Bank analyst Kai Klose maintained a Buy rating on LEG Immobilien today and set a price target of €85.00. According to TipRanks, Klose is ...

LEG Immobilien (0QC9) Gets a Buy from Berenberg Bank

In a report released today, Neil Green from J.P. Morgan maintained a Buy rating on LEG Immobilien, with a price target of €89.00. According to TipR...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	LEGN	$20.77	+1.94%	400.61K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	LEGN	$20.77	+1.9%	400.61K
3
4
5
6

LEGN

Get Legend Biotech Corporation Data in Excel

Get Legend Biotech Corporation Data in Excel